Tamara Vokes to Double-Blind Method
This is a "connection" page, showing publications Tamara Vokes has written about Double-Blind Method.
Connection Strength
0.299
-
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab. 2018 02 01; 103(2):722-731.
Score: 0.102
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
Score: 0.043
-
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):951-960.
Score: 0.042
-
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. J Bone Miner Res. 2022 12; 37(12):2435-2442.
Score: 0.035
-
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
Score: 0.034
-
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017 Jan; 55(1):273-282.
Score: 0.023
-
Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):275-83.
Score: 0.019